

# The effect of a unique omega-3 supplement on dry mouth and dry eye in Sjogren's patients

<b>Submission date</b> 07/02/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 27/03/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 04/11/2008	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Athena Papas

### Contact details

Tufts University School of Dental Medicine  
One Kneeland Street, Room 508  
Boston  
United States of America  
02111  
+1 617 636 3931  
athena.papas@tufts.edu

## Additional identifiers

### Protocol serial number

N/A

## Study information

### Scientific Title

### Study objectives

Use of omega-3 supplements can increase oral and ocular comfort and increase salivary flow in Sjogren's patients.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Ethics approval received from the Institutional Review Board - Tufts University Health Sciences /Tufts - New England Medical Center on the 16th May 2005 (ref: 7370)

### **Study design**

Prospective, randomised, placebo-controlled, double-masked clinical trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Sjogren's syndrome

### **Interventions**

Use of an omega-3 supplement (TheraTears Nutrition, Advanced Vision Research, USA) containing 750 mg of long-chain omega-3s (450 mg of eicosapentaenoic acid [EPA] and 300 mg of docosahexaenoic acid [DHA]) and 1000 mg of flaxseed oil designed to suppress inflammation and increase tear and saliva production.

The participants in the intervention group took the supplement once a day for 3 months.

### **Intervention Type**

Other

### **Phase**

Not Specified

### **Primary outcome(s)**

Increased oral and ocular comfort at 3 months

### **Key secondary outcome(s)**

Increased salivary flow and improvement in gingival index (GI) at 3 months

### **Completion date**

04/09/2007

## **Eligibility**

### **Key inclusion criteria**

Subjects with Sjogren's syndrome as defined by the European Criteria and a positive blood test or lip biopsy

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

1. Had less than 10 teeth
2. Received periodontal therapy in the past 12 months or antibiotic therapy in the past 1 month
3. Required pre-medication with antibiotics
4. Had advanced periodontitis, an infectious or wasting disease
5. Already supplementing with omega-3s
6. Participating in another clinical trial

**Date of first enrolment**

07/07/2005

**Date of final enrolment**

04/09/2007

**Locations****Countries of recruitment**

United States of America

**Study participating centre**

Tufts University School of Dental Medicine

Boston

United States of America

02111

**Sponsor information****Organisation**

Advanced Vision Research (USA)

**Funder(s)**

**Funder type**

Industry

**Funder Name**

Advanced Vision Research (USA)

## **Results and Publications**

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration